0901 BtS35 FDA vs EMA
dBioCentury

Back to School 2021

Quantifying overlap in FDA and EMA expedited approvals

Though they agree one third of the time, the two agencies often make different decisions on the same data

Though they agree one third of the time, the two agencies often make different decisions on the same data.

Sep 1, 2021 | 1:15 PM GMT

The U.S. and EU are expediting a similar number of drug approvals and converting the initial approvals to full approval at a similar rate. But a drug-by-drug analysis shows the two regulators often make different decisions on the same products.

BioCentury identified 196 drugs approved under the expedited pathways, of which 57 (29%) received an expedited approval in both territories. The analysis

Read the full 1241 word article

How to gain access

Continue reading with a
two-week free trial.